Transcatheter Aortic Valve Replacement Market outlook through 2035, highlighting key trends, growth drivers, challenges, and future opportunities ...

Patients with severe aortic stenosis at low surgical risk who underwent supra-annular, self-expanding Evolut transcatheter ...

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had an overall mortality rate of just 8.1% at one year, well below the trial's ...

Medtronic, Abbott and Boston Scientific had updates on their devices used in heart valve disease treatment at the event.

Aortic valve stenosis' is an often-overlooked condition and a growing health concern in ageing societies such as Thailand. With an increasing elderly population and a rise in age-related valve ...

Cardiothoracic Surgeon Geoffrey R. Cousins, MD, FACS, left, and Interventional Cardiologist Jason Schott, DO, mark the 100th transcatheter aortic valve replacement procedure performed at Memorial ...

Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing transcatheter aortic valve replacement (TAVR) were significantly less likely ...

Medtronic has reported late-breaking data from the Evolut Low Risk Trial’s five-year outcomes of the Evolut TAVR system.

The mortality rate associated with valve replacement is “worse ... out again through the pulmonary and aortic valves. Over a lifetime, heart valves open and shut billions of times.